Safety and performance Evidence
HDx therapy delivers meaningful and relevant innovation for dialysis patients.
Safety and Performance
Designed to expand treatment possibilities in renal care, HDx enabled by Theranova provides efficient removal of large middle molecules (25 kDa to <60 kDa) while selectively retaining essential proteins and maintaining stable albumin levels all to unlock new treatment possibilities.1-4
Importance of Safety and Performance
Reduced levels of uremic solutes might indicate a reduced degree of uremic toxicity. Evaluation can be made in vivo and/or in vitro and is assessed over the course of a single treatment.
Primary clinical studies illuminate the benefits of HDx therapy enabled by Theranova
Weiner DE et al. Efficacy and safety of expanded hemodialysis with the Theranova 400 dialyzer: A randomized controlled trial.
Theranova provides significant and superior removal of conventional/large middle molecules compared to conventional hemodialysis while retaining stable albumin levels.3
Krishnasamy R et al. A trial evaluating mid out-off value membrane clearance of albumin and light chains in hemodialysis patients (REMOVAL-HD): a safety device study.
Theranova efficiently removes middle molecules up to 45 kDa, such as lambda-FLC, while maintaining stable serum albumin levels, with only 0.7g/L decline in overall serum concentrations.1
Bunch A et al. Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH Registry.
Theranova is safe and preserves serum albumin levels within the normal range among patients undergoing expanded hemodialysis (HDx).5
Kirsch AH, et al. Performance of hemodialysis with novel medium cut-off dialyzers.
Theranova provides efficient removal of large middle molecule uremic toxins compared to traditional high flux membranes used during high-flux hemodialysis and hemodiafiltration, with limited albumin between 1 and 4g per treatment.2
Cantaluppi V, et al. Removal of large-middle molecules on expanded hemodialysis (HDx): a multicentric observational study of 6 months follow-up.
In a multi-centric observational study of 41 HD patients, pre-dialysis levels of β2 microglobulin and kappa and lambda free light chains were reduced after 3 and 6 months with HDx therapy using the Theranova dialyzer.6
Wolley M, Jardine M, Hutchison CA. Exploring the clinical relevance of providing increased removal of large middle molecules.
Theranova improves removal of middle-molecule uremic toxins that have been linked to the development of chronic inflammation, CVD, and other dialysis related comorbidities; this may result in improved patient outcomes.7
Ronco C and Clark WR. Hemodialysis membranes.
Theranova features an increased pore density with tight pore-size distribution, enhancing ultra-filtration and permeability via a steep sieving-curve — resulting in clearance of larger uremic toxins, while retaining essential proteins.8
Boschetti-de-Fierro A et al. MCO membranes: enhanced selectivity in high-flux class.
Tailored pore sizes of the Theranova membranes promote removal of an expanded range of uremic toxins, while ensuring retention of albumin. MCO’s unique membrane design allows for a filtration profile that’s closer to the natural kidney.4
Schepers E et al. Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis set-up.
The permeability of the Theranova membrane for endotoxins was not significantly different when comparing low flux, high-flux, medium cut-off, and high cut-off membranes.9
Provide Expanded Hemodialysis. Retain HD Simplicity.
Reference library
Hear from patients, nephrologists, and nurses alike share their experience prescribing HDx. Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialyzers are made.
HDx Evidence Compendium
On-going research and clinical reporting are an integral part of the HDx journey. Explore the expanding evidence related to HDx enabled by Theranova that nephrologists around the world continue to generate.
HDx Therapy Brochure
Here you can find the HDx therapy brochure with more information about prescribing HDx for your hemodialysis patients.
![HDx_page_600x260[1].png](/sites/g/files/ebysai2501/files/styles/small_tile_image/public/2020-11/HDx_page_600x260%5B1%5D.png?itok=Au8AQEk-)
HDx Therapy Specification Sheets
Here you can find the detailed profiles of Theranova dialyzers.
Important Safety Information:
Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
*Do not use Theranova dialyzers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.
CE 2797